Vitamin K antagonists (VKAs) or non-vitamin K oral anticoagulants (NOACs) are necessary to prevent stroke in patients with AF [2,3], whereas dual antiplatelet therapy (DAPT) with P2Y12 inhibitors and aspirin is required to prevent stent thrombosis in patients undergoing PCI [4,5]. This evidence concerns the gene P2RY12 and atrial fibrillation.